Primary Care
Coronary heart disease prevention: insights from modelling incremental cost effectiveness
BMJ 2003; 327 doi: https://doi.org/10.1136/bmj.327.7426.1264 (Published 27 November 2003) Cite this as: BMJ 2003;327:1264Related articles
- This Week In The BMJ Published: 27 November 2003; BMJ 327 doi:10.1136/bmj.327.7426.0-b
- Editor's Choice Published: 27 November 2003; BMJ 327 doi:10.1136/bmj.327.7426.0-g
- Editorial Published: 27 November 2003; BMJ 327 doi:10.1136/bmj.327.7426.1237
- Letter Published: 12 February 2004; BMJ 328 doi:10.1136/bmj.328.7436.405
- Letter Published: 12 February 2004; BMJ 328 doi:10.1136/bmj.328.7436.405-b
- Letter Published: 12 February 2004; BMJ 328 doi:10.1136/bmj.328.7436.405-c
- Letter Published: 12 February 2004; BMJ 328 doi:10.1136/bmj.328.7436.404-a
- Letter Published: 12 February 2004; BMJ 328 doi:10.1136/bmj.328.7436.405-a
See more
- Introductory AddressProv Med Surg J October 03, 1840, s1-1 (1) 1-4; DOI: https://doi.org/10.1136/bmj.s1-1.1.1
- Report of the Meeting of the Eastern Branch of the Provincial Association at Bury St. Edmond'sProv Med Surg J October 03, 1840, s1-1 (1) 10-13; DOI: https://doi.org/10.1136/bmj.s1-1.1.10
- Mr. Warburton's Bill for the Regulation of the Medical ProfessionProv Med Surg J October 03, 1840, s1-1 (1) 13-15; DOI: https://doi.org/10.1136/bmj.s1-1.1.13
- An Atlas of Plates, illustrative of the Principles and Practice of Obstetric Medicine and Surgery, with descriptive LetterpressProv Med Surg J October 03, 1840, s1-1 (1) 4; DOI: https://doi.org/10.1136/bmj.s1-1.1.4
- A Practical Treatise on the Diseases peculiar to Women, illustrated by Cases, &cProv Med Surg J October 03, 1840, s1-1 (1) 4-5; DOI: https://doi.org/10.1136/bmj.s1-1.1.4-a
Cited by...
- The polypill: at what price would it become cost effective?
- Treating hypertension with guidelines in general practice
- Prevention of coronary heart disease: Is a cure too expensive?
- Prevention of coronary heart disease: Statins are even less effective than paper shows
- Prevention of coronary heart disease: Data in table 2 could be shown more explicitly for better understanding
- Prevention of coronary heart disease: Incremental cost effectiveness raises issues
- What do we gain from the sixth coronary heart disease drug?